RxDoctor Payments Data

Jason Lappe

Clinical Cardiac Electrophysiology · Durham, NCNPI 1457594301

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (39.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Medtronic at 50.8% of the total. 2025 is the largest year on record at $25,065, more than ten times the $1,508 reported in 2019.

$42,898in general payments, 2019–2025

Across 300 payments — averaging $142.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$22K
  • Boston Scientific$9K
  • Biosense Webster, Inc.$6K
  • Abbott$3K
  • Atricure, Inc.$1K
  • Biotronik Inc.$537
  • plus $2K from 11 others

What the payments were for

  • Consulting fees$8,24919%
  • Speaking & faculty fees$17,05040%
  • Travel & lodging$4,72411%
  • Food & beverage$12,87430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,898 in reported general payments places this provider in the 65th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.

See all clinical cardiac electrophysiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$334,913
Medicare patients
791
Services billed
4,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban284$334,003
XareltoRivaroxaban121$135,006
MultaqDronedarone Hcl43$74,004
EntrestoSacubitril/Valsartan23$33,910
Dofetilide135$30,287
Metoprolol Succinate280$5,258
Flecainide Acetate100$3,699
Diltiazem 12hr ErDiltiazem Hcl11$3,229
Mexiletine Hcl13$1,837
Amiodarone Hcl111$1,487
Mupirocin131$999
SotalolSotalol Hcl52$985
Torsemide34$712
Losartan Potassium54$567
Amlodipine Besylate59$451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$253$334,003284 claims
Johnson & JohnsonXarelto$91$135,006121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.

Other clinical cardiac electrophysiology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →